TWI805705B - 選擇性syk抑制劑之使用方法及醫藥組合物 - Google Patents

選擇性syk抑制劑之使用方法及醫藥組合物 Download PDF

Info

Publication number
TWI805705B
TWI805705B TW108107933A TW108107933A TWI805705B TW I805705 B TWI805705 B TW I805705B TW 108107933 A TW108107933 A TW 108107933A TW 108107933 A TW108107933 A TW 108107933A TW I805705 B TWI805705 B TW I805705B
Authority
TW
Taiwan
Prior art keywords
compound
ophthalmic composition
eye
aqueous ophthalmic
allergic conjunctivitis
Prior art date
Application number
TW108107933A
Other languages
English (en)
Chinese (zh)
Other versions
TW202002980A (zh
Inventor
安傑禮 潘迪
馬修 恰品
哈洛德 派特森
永越 徐
馬克 阿貝爾森
Original Assignee
美商普托拉製藥有限公司
美商歐拉有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商普托拉製藥有限公司, 美商歐拉有限公司 filed Critical 美商普托拉製藥有限公司
Publication of TW202002980A publication Critical patent/TW202002980A/zh
Application granted granted Critical
Publication of TWI805705B publication Critical patent/TWI805705B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108107933A 2018-03-09 2019-03-08 選擇性syk抑制劑之使用方法及醫藥組合物 TWI805705B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862641094P 2018-03-09 2018-03-09
US62/641,094 2018-03-09
US201862663999P 2018-04-27 2018-04-27
US62/663,999 2018-04-27

Publications (2)

Publication Number Publication Date
TW202002980A TW202002980A (zh) 2020-01-16
TWI805705B true TWI805705B (zh) 2023-06-21

Family

ID=65818744

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108107933A TWI805705B (zh) 2018-03-09 2019-03-08 選擇性syk抑制劑之使用方法及醫藥組合物

Country Status (15)

Country Link
US (1) US20210052582A1 (https=)
EP (1) EP3761986A1 (https=)
JP (1) JP7417531B2 (https=)
KR (1) KR20210018193A (https=)
CN (2) CN112243375A (https=)
AU (1) AU2019230220B2 (https=)
BR (1) BR112020018377A2 (https=)
CA (1) CA3093371A1 (https=)
IL (1) IL277093A (https=)
MX (1) MX2020009396A (https=)
PH (1) PH12020551418A1 (https=)
SG (1) SG11202008765UA (https=)
TW (1) TWI805705B (https=)
WO (1) WO2019173744A1 (https=)
ZA (1) ZA202005459B (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274216A1 (en) * 2012-04-12 2013-10-17 Alcon Research, Ltd. Treatment for microbe-induced inflammatory responses in the eye
WO2014045029A1 (en) * 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
US20150297595A1 (en) * 2008-04-16 2015-10-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and jak protein kinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
KR101454674B1 (ko) 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
SG2014015085A (en) * 2008-04-16 2014-06-27 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
KR20140103168A (ko) * 2011-12-16 2014-08-25 알러간, 인코포레이티드 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150297595A1 (en) * 2008-04-16 2015-10-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and jak protein kinases
US20130274216A1 (en) * 2012-04-12 2013-10-17 Alcon Research, Ltd. Treatment for microbe-induced inflammatory responses in the eye
WO2014045029A1 (en) * 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors

Also Published As

Publication number Publication date
SG11202008765UA (en) 2020-10-29
US20210052582A1 (en) 2021-02-25
AU2019230220A1 (en) 2020-10-08
KR20210018193A (ko) 2021-02-17
PH12020551418A1 (en) 2021-09-01
MX2020009396A (es) 2021-01-15
IL277093A (en) 2020-10-29
BR112020018377A2 (pt) 2021-03-09
AU2019230220B2 (en) 2025-01-30
CN119235862A (zh) 2025-01-03
JP2021517139A (ja) 2021-07-15
CA3093371A1 (en) 2019-09-12
EP3761986A1 (en) 2021-01-13
JP7417531B2 (ja) 2024-01-18
WO2019173744A1 (en) 2019-09-12
CN112243375A (zh) 2021-01-19
ZA202005459B (en) 2023-02-22
TW202002980A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
CN1753683B (zh) 预防和治疗不良眼部病症的眼用制剂
EP4272743A2 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US20210177807A1 (en) Compositions for the treatment and prevention of eyelid swelling
ES2910374T3 (es) Formulaciones oftálmicas de cetirizina y procedimientos de uso
EP2219630A2 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
AU2011334617B2 (en) Folic acid - Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
CN101754748A (zh) 治疗干眼症的制剂和方法
BR112021015737A2 (pt) Formulações de 4-(7-hidróxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrila
WO2008027793A2 (en) Ophthalmic pharmaceutical compositions and uses thereof
TW202245810A (zh) 散光之治療
Sarmento et al. Can (Natural) deep eutectic systems increase the efficacy of ocular therapeutics?
TWI805705B (zh) 選擇性syk抑制劑之使用方法及醫藥組合物
TWI852041B (zh) 採用長春西汀治療近視的方法
Bandyopadhyay et al. Development of ophthalmic formulations
Smith et al. Tolerability, pharmacokinetics, and pharmacodynamics of a brinzolamide episcleral sustained release implant in normotensive New Zealand white rabbits
RU2836815C1 (ru) Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
CN103202833A (zh) 一种奥洛他定或其盐的药用组合物及其制备方法
TW201028176A (en) Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
JP2013103919A (ja) クロルフェニラミンマレイン酸塩を含有する徐放性フィルム製剤

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees